Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 65

1.

Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.

J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936. Epub 2015 Jan 29.

PMID:
25635138
2.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW.

Rev Urol. 2014;16(4):172-80.

3.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2014 Nov 29. pii: S0302-2838(14)01213-5. doi: 10.1016/j.eururo.2014.11.030. [Epub ahead of print]

4.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

PMID:
24836057
5.

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.

Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.

6.

Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Spritzer CE, Afonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A, Madden JF, Roy Choudhury K, Febbo PG, George DJ.

Radiology. 2013 Dec;269(3):816-23. doi: 10.1148/radiol.13121782. Epub 2013 Oct 28.

7.

Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.

Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ.

Prostate. 2013 May;73(7):754-62. doi: 10.1002/pros.22619. Epub 2012 Nov 28.

8.

Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.

Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, Georgiev SG, Coetzee GA, Ohler U, Furey TS, Crawford GE, Febbo PG.

Genome Biol. 2012 Oct 3;13(10):R88. doi: 10.1186/gb-2012-13-10-r88.

9.

Predictive biomarkers in advance of a companion drug: ahead of their time?

Kelley RK, Atreya C, Venook AP, Febbo PG.

J Natl Compr Canc Netw. 2012 Mar;10(3):303-9.

PMID:
22393192
10.

Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.

Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS.

Mol Cancer Ther. 2012 Jul;11(7):1500-9. doi: 10.1158/1535-7163.MCT-11-0937. Epub 2012 Feb 16.

11.

An animal model of MYC-driven medulloblastoma.

Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.

12.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16.

PMID:
22203777
13.

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML.

J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33.

PMID:
22138009
14.

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Stewart SB, BaƱez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.

J Urol. 2012 Jan;187(1):103-8. doi: 10.1016/j.juro.2011.09.040. Epub 2011 Nov 16.

PMID:
22088334
15.

Immune signatures predict prognosis in localized cancer.

Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG.

Cancer Invest. 2010 Aug;28(7):765-73. doi: 10.3109/07357900903095755.

PMID:
20569070
16.

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA.

Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.

17.

MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy.

Balakumaran BS, Herbert JT, Febbo PG.

Autophagy. 2010 Feb;6(2):281-2. Epub 2010 Feb 10.

18.

Cancer gene profiling in prostate cancer.

Foye A, Febbo PG.

Methods Mol Biol. 2010;576:293-326. doi: 10.1007/978-1-59745-545-9_15.

PMID:
19882268
19.

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG.

Cancer Res. 2009 Oct 1;69(19):7803-10. doi: 10.1158/0008-5472.CAN-09-0910. Epub 2009 Sep 22.

20.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk